TITLE

THEORETICAL AND PRACTICAL ASPECTS OF THROMBOLYTIC THERAPY

AUTHOR(S)
Hirsh, J.
PUB. DATE
January 1977
SOURCE
Angiology;Jan1977, Vol. 28 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Provides some insights into the theoretical and practical aspects of thrombolytic therapy. Feasibility of producing the dissolution of thrombi and emboli by the plasminogen activators streptokinase and urokinase; Production of fibrinolysis by the plasminogen activators by converting the pro-enzyme plasminogen into the active enzyme plasmin; Susceptibility of fibrin to dissolution by plasmin.
ACCESSION #
16456791

 

Related Articles

  • THROMBOLYTIC THERAPY: DIFFERENCES BETWEEN STREPTOKINASE AND UROKINASE. Bell, William R. // Vascular Surgery;Nov/Dec1977, Vol. 11 Issue 6, p378 

    Compares the relative potency of streptokinase and urokinase as agents for thrombolytic therapy in patients with pulmonary emboli. Therapeutic regimens of streptokinase and urokinase; Biochemical properties of streptokinase and urokinase; Assessment of the therapeutic improvement after the...

  • Fibrin Binding and the Regulation of Plasminogen Activators during Thrombolytic Therapy. Longstaff, C.; Williams, S.; Thelwell, C. // Cardiovascular & Hematological Agents in Medicinal Chemistry;2008, Vol. 6 Issue 3, p212 

    First generation thrombolytics (streptokinase and urokinase) had no fibrin binding capabilities and caused systemic plasminogen activation with concomitant destruction of haemostatic proteins. A primary driving force behind the development of the second generation plasminogen activator tissue...

  • Should Thrombolytic Therapy Be Used in Patients with Pulmonary Embolism? Stavros Konstantinides // American Journal of Cardiovascular Drugs;2004, Vol. 4 Issue 2, p69 

    More than thirty years have passed since streptokinase was first shown to dissolve pulmonary arterial thrombi and normalize pulmonary artery pressure in patients with acute pulmonary embolism (PE). Following the initial observations, a number of controlled clinical trials confirmed that...

  • Tissue plasminogen activator for thrombolytic therapy: expectation versus reality. Gaffney, P. J. // Journal of the Royal Society of Medicine;Nov1992, Vol. 85 Issue 11, p692 

    The article discusses the use of DNA technology in thrombolytic therapy. DNA technology produces recombinant tissue plasminogen activator (rt-PA). This reduces the complications involved with other thrombolytic agents like streptokinase and urokinase. The structure and function of rt-PA are...

  • Streptokinase. Vohr, Hans-Werner // Encyclopedic Reference of Immunotoxicology;2005, p611 

    An encyclopedia entry for the term "streptokinase" is presented. Streptococcus pyrogenes produces the enzyme streptokinase which activates the plasminogen activator. Plasminogen activator catalyses the conversion of plasminogen in plasmin.

  • Site-restricted plasminogen activation mediated by group A streptococcal streptokinase variants. COOK, Simon M.; SKORA, Amanda; WALKER, Mark J.; SANDERSON-SMITH, Martina L.; MCARTHUR, Jason D. // Biochemical Journal;2/15/2014, Vol. 458 Issue 1, p23 

    SK (streptokinase) is a secreted plasminogen activator and virulence factor of GAS (group A Streptococcus). Among GAS isolates, SK gene sequences are polymorphic and are grouped into two sequence clusters (cluster type-1 and cluster type- 2) with cluster type-2 being further classified into...

  • Thermodynamic Characteristics of Plasminogen Activation by Indirect Activators. Sokolovskaya, L. I.; Volkov, G. L. // Biochemistry (00062979);Oct2005, Vol. 70 Issue 10, p1145 

    Several indirect plasminogen (Pg) activators are known including streptokinase and the monoclonal antibody IV-Ic, whose mechanism of activation is well studied. To characterize thermodynamically the activation of Pg by streptokinase (SK) and the monoclonal antibody (mAB) IV-Ic, the activation...

  • Monitoring of Plasmin and Plasminogen Activator Activity in Blood of Patients under Fibrinolytic Treatment by Reteplase. Stief, T. W.; Richter, A.; Bünder, R.; Maisch, B.; Renz, H. // Clinical & Applied Thrombosis/Hemostasis;Apr2006, Vol. 12 Issue 2, p213 

    There are no reliable data on plasmin or plasminogen activator (PA) activities in blood of patients receiving fibrinolytic treatment. This is due to continuing in vitro action of PA after blood withdrawal. These artefactual changes of PA or plasmin activities have been prevented by arginine...

  • Fibrinolysis at the Fluid-Solid Interface of Thrombi. Kolev, K.; Longstaff, C.; Machovich, R. // Current Medicinal Chemistry - Cardiovascular & Hematological Age;Oct2005, Vol. 3 Issue 4, p341 

    Thrombolysis is conventionally regarded as dissolution of the fibrin matrix of thrombi by plasmin, a protease generated by plasminogen activators from its inactive precursor, plasminogen. Typically plasminogen activation occurs on the surface of the clot, where fibrin behaves as a cofactor in...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics